Hyperprogressive disease in patients with non‐small cell lung cancer treated with nivolumab: A case series

Nivolumab is an anti‐PD‐1 blocking monoclonal antibody approved for the treatment of non‐small cell lung cancer (NSCLC). However, some patients on immunotherapy may experience rapid progression and worsening clinical status, known as hyperprogressive disease. We retrospectively reviewed the clinical...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Thorac Cancer
Hauptverfasser: Kanazu, Masaki, Edahiro, Ryuya, Krebe, Hiroyuki, Nishida, Kohei, Ishijima, Mikako, Uenami, Takeshi, Akazawa, Yuki, Yano, Yukihiro, Yamaguchi, Toshihiko, Mori, Masahide
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley & Sons Australia, Ltd 2018
Schlagworte:
Case Reports
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6275832/
https://ncbi.nlm.nih.gov/pubmed/30328672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12894
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge